Hematological Disorders in EHPVO Patients
- Sponsor
- Rahab Nady
- Study ID
- NCT07108023
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Anemia
- Antiphospholipid Syndrome (APS)
- Extrahepatic Portal Vein Obstruction (EHPVO)
- Leukopenia
- Myeloproliferative Neoplasms (MPN)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Thrombocytopenia
- Thrombophilia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- No intervention (Observational Study) — OTHERThis is a retrospective observational study with no assigned intervention. Data will be collected from patient medical records only
Study Details
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver. This blockage can cause problems like an enlarged spleen, bleeding from swollen veins in the digestive system, and low blood cell counts. Many of these patients may have hidden blood disorders that increase the risk of clotting, such as myeloproliferative neoplasms (MPNs), antiphospholipid syndrome (APS), or paroxysmal nocturnal hemoglobinuria (PNH). This study will collect and analyze blood test results-such as complete blood count (CBC), liver function tests (LFTs), and clotting tests-from patients with EHPVO. The aim is to find patterns that may suggest an underlying blood disorder, even if the patient doesn't show obvious symptoms.By understanding these patterns early, doctors may be able to diagnose and treat the root causes of clotting in these patients more accurately, helping prevent complications and improve outcomes.
Key Dates
- Start date
- Aug 31, 2025
- Status verified
- Jul 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 115 participants (estimated)
Arms
- Arm: EHPVO PatientsPatients diagnosed with extrahepatic portal vein obstruction (EHPVO) based on imaging (Doppler ultrasound, CT, or MRI) and with preserved liver function. This group will be assessed for hematological abnormalities, including cytopenias and coagulation disturbances, using retrospective laboratory data.
Primary Outcome Measure
Frequency of hematological disorders in EHPVO patients [ Time Frame: Over a retrospective period from 2020 to 2024 ]
Central Contacts
- Rehab N Dr Rehab Nady Ali+201099703970
Related Studies
- Diamond Blackfan Anemia Registry (DBAR)Recruiting · Northwell Health · New Hyde Park, New York
- A Phase I Study of Mozobil in the Treatment of Patients With WHIMSPHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening AnemiaEnrolling By Invitation · Englewood Hospital and Medical Center · Englewood, New Jersey
- Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD ProphylaxisPHASE2 · Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland